RESEARCH ARTICLE

Accurate FDG PET tumor segmentation using the peritumoral halo layer method: a study in patients with esophageal squamous cell carcinoma

Sungmin Jun¹, Jung Gu Park² and Youngduk Seo³*

Abstract

Background: In a previous study, FDG PET tumor segmentation (SegPHL) using the peritumoral halo layer (PHL) was more reliable than fixed threshold methods in patients with thyroid cancer. We performed this study to validate the reliability and accuracy of the PHL method in patients with esophageal squamous cell carcinomas (ESCCs), which can be larger and more heterogeneous than thyroid cancers.

Methods: A total of 121 ESCC patients (FDG avid = 85 (70.2%); FDG non-avid = 36 (29.8%)) were enrolled in this study. In FDG avid ESCCs, metabolic tumor length (ML) using SegPHL (ML_PHL), fixed SUV 2.5 threshold (ML_2.5), and fixed 40% of maximum SUV (SUVmax) (ML_40%) were measured. Regression and Bland-Altman analyses were performed to evaluate associations between ML, endoscopic tumor length (EL), and pathologic tumor length (PL). A comparison test was performed to evaluate the absolute difference between ML and PL. Correlation with tumor threshold determined by the PHL method (PHL tumor threshold) and SUVmax was evaluated.

Results: ML_PHL, ML_2.5, and ML_40% correlated well with EL (R² = 0.6464, 0.5789, 0.3321, respectively; p < 0.001) and PL (R² = 0.8778, 0.8365, 0.6266, respectively; p < 0.001). However, ML_2.5 and ML_40% showed significant proportional error with regard to PL; there was no significant error between ML_PHL and PL. ML_PHL showed the smallest standard deviation on Bland-Altman analyses. The absolute differences between ML and PL were significantly smaller for ML_PHL and ML_40% than for ML_2.5 (p < 0.0001). The PHL tumor threshold showed an inverse correlation with SUVmax (d = -0.923, p < 0.0001).

Conclusions: SegPHL was more accurate than fixed threshold methods in ESCC. The PHL tumor threshold was adjusted according to SUVmax of ESCC.

Keywords: Peritumoral halo layer, Tumor segmentation, FDG PET/CT, Esophageal cancer, Reliability test, Tumor length

Introduction

F-18 fluorodeoxyglucose (FDG) PET/CT is a noninvasive modality for staging and localization of various malignant tumors that have high glucose metabolism. FDG PET/CT can provide a variety of metabolic parameters, such as maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV) [1, 2], total lesion glycolysis (TLG) [3], and metabolic tumor length (ML) [4, 5]. Among these, SUVmax is the most commonly used FDG PET parameter because the measurement is easy and operator independent. Although SUVmax is a widely used parameter, it is a representation of the highest metabolic value of only one pixel within a metabolically active tumor. Thus, the total burden of the primary tumor cannot be evaluated by SUVmax.

MTV and TLG can provide volumetric metabolic information on malignant tumors. MTV is a measurement of the volume of a tumor with a high metabolism, while TLG is defined as the product of mean SUV and MTV [6]. A variety of methods have been used to measure and

* Correspondence: mdbabduck@gmail.com
³Department of Nuclear Medicine, Busan Seongso Hospital, Suyeong-ro, Nam-gu, Busan 48453, Republic of Korea
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
segment MTV. These include visual segmentation methods (SegVisual), where the region of interest is drawn manually [7, 8], fixed SUV threshold methods (SegSUV) [3, 6], fixed percentage of SUVmax threshold methods (Seg%) [3, 6], adaptive threshold methods (SegAdaptive) [6, 9], and gradient methods (SegGradient) [6, 10, 11]. Among these various segmentation approaches, SegSUV or Seg% is widely used to measure MTV because nearly all PET/CT workstations have an auto-segmentation program for fixed threshold methods. Accurate segmentation of MTV is also important for accurate measurement of TLG. Because TLG is a product of MTV and mean SUV (SUVmean), accurate MTV segmentation is essential for reliable TLG measurement. Furthermore, an accurate SUVmean estimate also requires accurate MTV segmentation. If segmented MTV is largely different from the true pathologic tumor volume, TLG will be inaccurate. ML is the length of the tumor on the PET image. The threshold determination for ML is similar to that for MTV [12].

SegAdaptive and SegGradient are known to be more accurate than SegSUV or Seg% [6, 10, 11]. The main principle of SegAdaptive is to adapt the percentage threshold of the phantom or tumor according to signal-to-background ratio [6, 9, 13]. Several optimal regression functions can be obtained by fitting various regression models [6, 9, 13, 14]. MTV using SegGradient is a method used to detect a large gradient change in radioactivity around the tumor. The large gradient change is located in the outmost peripheral portion of the tumor, and its location is used to define the tumor margin [11, 15, 16]. However, a specialized program and workstation, PET Edge (MIM Software Inc., Cleveland, OH, USA), is needed to determine MTV using SegGradient.

Jun et al. [17] recently introduced a new method for MTV segmentation. They found a distinct layer between the tumor and background activity using a 10-step color scale with specific window level settings and named the distinct layer the “peritumoral halo layer (PHL).” Segmentation using the PHL method (SegPHL) was more reliable than MTV segmented by SegSUV or Seg%. Although SegPHL might be reliable, the previous study was performed in patients with a small and visually homogeneous type of tumor, namely papillary thyroid carcinoma [17]. Thus, further validation of large, heterogeneous tumors is needed to determine if SegPHL can be widely applied in clinical settings.

Our aim was to compare variously segmented MLs (i.e., ML segmented by SUV 2.5 (ML2.5), 40% of SUVmax (ML40%), and PHL (MLPHL)) of esophageal squamous cell carcinoma (ESCC) with pathological tumor length (PL) and to identify whether SegPHL could be used to reliably define tumor margin in ESCC, which can be large and/or heterogeneous.

Methods

Subjects

This retrospective study was approved by the institutional review board of our hospital and performed in accordance with the Helsinki Declaration. Between January 2013 and June 2017, 137 consecutive patients who had undergone pretreatment FDG PET/CT were evaluated for this study. Patient selection, main parameters, and evaluations are represented graphically in Fig. 1. Among the 137 patients, 16 were excluded for the following reasons: (1) conglomerated hypermetabolic metastatic lymph nodes (LNs) closely adjacent to the main hypermetabolic ESCC (n = 13, 2) invasion of the gastric cardia (n = 2), and intense physiologic left ventricular FDG uptake of the heart that was closely adjacent to the ESCC (n = 1). A total of 121 patients were finally enrolled in this study.

Among the 121 patients, 58 underwent esophagectomy, 2 underwent endoscopic submucosal dissection (ESD), 29 underwent concurrent chemoradiation therapy (CCRT), 1 underwent radiation therapy, 10 underwent chemotherapy only, and 21 were lost to follow-up. Reasons for non-operative therapy are illustrated in Fig. 1. Of the total patients, 111 (91.7%) were men, and 10 (8.3%) were women. Tumor locations were the upper third of the esophagus in 18 (14.9%), mid third in 64 (52.9%), lower third in 31 (25.6%), upper and mid esophagus in 6 (5.0%), and mid and lower esophagus in 2 (1.7%). The median age of the 121 patients at the time of FDG PET/CT pretreatment was 63 years (range: 33–85 years). The time interval between FDG PET/CT and esophagectomy or ESD was less than 6 weeks (median = 7.5 days; range = 1–39 days).

Measurement of endoscopic length

Among the 121 enrolled patients, 116 underwent evaluation of esophagogastroduodenoscopy (EGD) at our hospital (Table 1). Endoscopic length (EL) was routinely measured and reported by the operator in centimeters. The distance from the incisors was recorded on the basis of markings on the endoscope shaft at the distal edge of the ESCC. Thereafter, the endoscope was drawn to the proximal edge of the ESCC. The distance from the incisors was again estimated. EL was defined as the difference in the distances of the proximal and distal edges from the incisors [18].

Acquisition of FDG PET/CT

Patients fasted for at least six hours before FDG injection (370–444 MBq). Serum glucose level was measured before FDG injection. Scanning was performed 50–70 min after injection of FDG using a Biograph Duo PET/CT scanner (Siemens Healthcare, Erlangen, Germany) or a Biograph 16 PET/CT scanner (Siemens Healthcare, Erlangen, Germany).
Patients were asked to rest before acquisition of PET/CT images. Before the PET scan, a low-dose CT scan (5 mm slices) at an interval of 5 mm was performed for attenuation correction and anatomic co-registration. Intravenous contrast material was not used. PET images were acquired using an acquisition time of 3 min per table position, with an approximate 28% overlap. Images were obtained from the skull base to the proximal thigh with the patient in supine position. Images were reconstructed by a 3D row-action maximum-likelihood algorithm for iterative and ordered-subset expectation maximization using the Biograph system. PET images were corrected for attenuation using a CT-derived transmission map. Voxel size after reconstruction was $2.65 \times 2.65 \times 2.65$ mm.

Identification of PHL and determination of tumor threshold on FDG PET/CT
All FDG PET/CT studies were reviewed on a workstation (Siemens Syngo.via, Siemens Healthcare, Erlangen, Germany). First, we evaluated FDG avidity of the primary ESCC. We considered ESCC to be FDG-avid if abnormal focal or ellipsoid tumoral hypermetabolic activity was visible in the esophagus. If there was no abnormal
FDG-avid lesion, we recorded the case as FDG-non-avid ESCC. We measured the SUVmax of FDG-avid ESCCs. The PHL was identified, and the tumor threshold (PHL tumor threshold) was determined as described by Jun and colleagues for papillary thyroid cancer [17]. ESCCs, however, can be visually heterogeneous, unlike papillary thyroid carcinomas, which are almost always small and visually homogeneous. Therefore, the visual tumor pattern was also described in this section.

An example of identification of PHL and PHL tumor threshold is provided in Fig. 2. PET window level and color scale for PHL identification (PHL image settings) were set as follows:

1. PET contrast window level was set in SUV units (not Bq/mL or % units);
2. The top value of the window level was set slightly higher than the SUVmax of the ESCC (e.g., if the SUVmax was 13.00 – 13.09, the top value was set to 13.1), and the bottom value was set to 0;
3. Color scale was changed to a 10-step color scale. We used the Spectrum 10 scale of our workstation.

After inputting these settings, the PHL and PHL tumor threshold were identified according to the following steps:

1. The view around the ESCC was magnified for accurate identification of the PHL.
2. The PHL was identified by an abrupt increase in layer thickness with minimal or mild distortion of the main tumor contour and was between tumoral uptake and background activity [17]. In the present study, the PHL was easy to determine by examining magnified MIP images.
3. The PHL tumor threshold was determined using PHL. Using the PHL imaging settings described above, each color layer represents 10% of the SUVmax. PHL was located between the tumor and the background. Thus, the outermost point of the tumor was the same as the innermost point of the PHL. If the PHL was located at 20–30% of SUVmax, the percentage SUVmax in the innermost portion of the PHL (i.e., PHL tumor threshold) was determined to be 30% (Fig. 2).

After this series of steps, tumoral uptake patterns were classified as visually homogeneous or visually heterogeneous [19]. Tumoral uptake of the ESCC comprised the hottest cores and regular or irregular tumor layers (not the PHL) (Fig. 3). In visually homogeneous ESCCs, the hottest core was located in the center of the ESCC and was surrounded by regular tumor layers (Fig. 3a). In contrast, in visually heterogeneous ESCCs, the hottest core or the hottest multiple cores were located in the eccentric portion of the tumor. In these heterogeneous tumors, several irregular inner layers were visible around the eccentric hottest core, and single or multiple regular outer layers of the tumor enveloped the hottest core and irregular inner layers (Figs. 3b, c). Regardless of visual tumor heterogeneity, the PHL was always located between tumoral uptake and background activity. Classification of visual tumor heterogeneity in our study was similar to that used by Tixier et al. [19] with the exception of the PHL image settings.

Table 1 Comparison of demographics and characteristics of primary esophageal SCCs according to FDG avidity on PET/CT (n = 121)

|                         | FDG-avid (n = 85) | FDG-non-avid (n = 36) | P value |
|-------------------------|-------------------|-----------------------|---------|
| Age (years)             |                   |                       |         |
| Median, range           | 63, 48–85         | 67, 33–81             | 0.5403  |
| Sex (male/female)       | 79/6              | 32/4                  | 0.4818  |
| Tumor location          |                   |                       |         |
| Upper third             | 14                | 4                     |         |
| Mid third               | 43                | 21                    |         |
| Lower third             | 20                | 11                    |         |
| Upper to mid            | 6                 | 0                     |         |
| Mid to lower            | 2                 | 0                     |         |
| Pretreatment endoscopy in our hospital (performed/not performed) | 83 / 2 | 33 / 3 | 0.1553 |
| Treatment methods       |                   |                       |         |
| Operation               | 37                | 22                    | 0.0405* |
| Endoscopic submucosal dissection | 0   | 1                     |         |
| Concurrent chemoradiation therapy | 25        | 4                     |         |
| Radiation therapy alone | 1                 | 0                     |         |
| Chemotherapy alone      | 9                 | 1                     |         |
| Follow-up loss without any therapy (follow-up loss/treatment in our hospital) | 13 / 72 | 8 / 28 | 0.4321 |

*Statistically significant
Fig. 2 Representative images to determine PHL tumor threshold and to measure $ML_{PHL}$ and $MTV_{PHL}$. Step 1 (upper): PHL image settings. A segmental hypermetabolic lesion ($SUV_{max} = 13.07$) is identified in the mid esophagus (upper left). The window level is set in SUV units. The top value is set to slightly higher than $SUV_{max}$ (top value $13.1 > 13.07$), and the bottom value is set to zero (upper middle). Thereafter, the color scale is changed to a 10-step color scale, which was Spectrum 10 in our study (upper right). A magnified view is used to determine background activity and PHL. Magnification of the ESCC (red dotted box) is performed. Step 2 (middle): Magnified view of the ESCC using PHL image settings (red dotted box in the upper right image). In this image, each layer represents $10\%$ of $SUV_{max}$. The hottest core is $> 90\%$ of $SUV_{max}$. There are two hot cores in this ESCC. PHL is located between the tumor and the background activity. In this image, the background activity is the dark blue layer (10–20% of $SUV_{max}$), and the PHL is located at 20–30% of $SUV_{max}$ (light blue layer; red arrows). Therefore, the PHL tumor threshold is $30\%$ of $SUV_{max}$ (i.e., the innermost portion of the PHL; red dotted arrow). Layer thickness increases abruptly in the PHL. Step 3 (lower): Measurement of $ML_{PHL}$ and $MTV_{PHL}$. After we determined PHL tumor threshold, we manually measured $ML_{PHL}$ using the ruler tool of the workstation (lower left). $MTV_{PHL}$ was measured by the auto-segmentation program after applying PHL tumor threshold (lower right; 30% of $SUV_{max}$ in this ESCC).
The locations of the PHL and visual tumor heterogeneity were determined by two nuclear medicine physicians who were blinded to pathologic tumor length (PL) and EL values. If the two physicians disagreed, the final decision was made by consensus.

**Measurements of metabolic tumor length**

After determination of PHL tumor threshold, we measured $ML_{PHL}$, $ML_{2.5}$, and $ML_{40\%}$ of the ESCC. A straight line was drawn using the ruler tool of our workstation in sagittal view (Fig. 2). $ML_{PHL}$ and $ML_{40\%}$ were measured using the PHL tumor threshold and fixed at 40% of $SUV_{max}$ on the PHL image setting. $ML_{2.5}$ was measured on SUV2.5 iso-contour images with a PET window bottom value of 2.50 SUV and a top value of 2.51 SUV. When $SUV_{max}$ of the tumor was lower than 2.5, $ML_{2.5}$ was recorded as 0.

**Evaluation of pathologic tumor length (pathologic reference standard)**

PL measurements of ESCCs are performed routinely in our hospital. PL was measured by the following procedure. An incision was made along the longitudinal esophageal axis. Thereafter, the esophageal specimen with a straight alignment was set on a flat table. The specimen was sent for pathological examination after preservation in 10% neutral buffered formalin. The PL of the ESCC specimen was measured using a ruler and recorded.

**Statistical analyses**

Major parameters and analyses in our study are presented in Fig. 1. Demographic and tumor data according to FDG avidity of ESCC were compared using Fisher’s exact test, chi-square test, or Mann-Whitney U test. Weighted
Kappa statistics were performed to evaluate inter-observer agreement between the two nuclear medicine physicians for PHL tumor threshold. Regression analyses were performed to evaluate the correlations between ML_{PHL}, ML_{2.5}, ML_{40%}, EL, and PL. Bland-Altman plots and Pearson correlation coefficients were used to evaluate the reliability of ML, EL, and PL. Relationships between PHL tumor threshold and SUVmax were evaluated by Spearman’s rank correlation. MedCalc® for Windows (MedCalc Software, Mariakerke, Belgium) was the statistical software package used for all statistical analyses.

**Results**

**Clinical situation according to FDG avidity of ESCC**

A total of 121 ESCC patients were enrolled in our study. Demographics and other characteristics of ESCCs according to FDG avidity are shown in Tables 1 and 2. There were 85 FDG avid ESCCs (visually homogeneous: n = 48; visually heterogeneous: n = 37) and 36 FDG non-avid ESCCs. FDG avidity of ESCCs was related to inoperability (p = 0.0405), EL (p = 0.0042), PL (p = 0.0001), presence of metastatic LNs on FDG PET/CT (p = 0.0005), presence of M1a metastatic LN or distant metastasis (p = 0.0037), and pathologic depth of invasion (p < 0.0001). The frequency of metastatic LNs on pathologic specimens tended to be higher in FDG avid ESCCs than in FDG non-avid ESCCs but without statistical significance (p = 0.0941). Age, sex, and tumor location did not differ according to FDG avidity of ESCC.

**Inter-observer agreement for PHL determination**

Tumor segmentation by PHL was available for all FDG-avid ESCCs (n = 85). Inter-observer agreement for PHL tumor threshold was very good (k = 0.936) (Table 3).

**Correlations between ML and EL in FDG-avid ESCCs and reliability testing**

In 121 study patients, pretreatment EGD was performed in 116. Among the 116 patients, EL was measured in 114; measurements were impossible in two patients because of esophageal obstruction (Table 2). The median EL in the 114 patients was 3.0 cm (range 0.5–9.0 cm; interquartile range 2.0–5.0 cm). Among the 85 patients with FDG avid ESCC, EGD was performed for 83 (Table 1). EL was measured in 81 of those patients, while EL measurement was impossible in 2 patients because the endoscope could not pass through the ESCC. Therefore, MLs (ML_{PHL}, ML_{2.5}, and ML_{40%}) and EL were compared in 81 patients. The median EL was 3.5 cm in FDG avid ESCCs (range 1.0–9.0 cm) (Table 2). Medians of ML_{PHL}, ML_{2.5}, and ML_{40%} were 3.81 cm (range 0.80–9.80 cm), 4.80 cm (range 0.00–10.30 cm), and 4.40 cm (range 1.88–9.39 cm), respectively. In the 85 FDG avid ESCCs, the endoscopic length, pathologic length, and frequency of metastasis according to FDG avidity of the primary ESCC are shown in Table 2.

**Table 2** Comparison of endoscopic length, pathologic length, and frequency of metastasis according to FDG avidity of the primary ESCC

| FDG-avid (n = 85) | FDG-non-avid (n = 36) | P value |
|-------------------|-----------------------|---------|
| Endoscopic passage to distal portion of the tumor* (possible/impossible) | 81/2 | 33/0 | 1.0000 |
| Endoscopic length (cm)** | 3.5, 1.0–9.0 | 2.0, 0.5–9.0 | 0.0042† |
| Pathologic length (cm)*** | 3.5, 0.9–7.6 | 1.7, 0.15–6.0 | 0.0001† |
| Metastatic LN on FDG PET/CT (yes/no) | 40 / 45 | 5 / 31 | 0.0005† |
| M1a metastatic LN or distant metastasis on FDG PET/CT (yes/no) | 21 / 64 | 1 / 35 | 0.0037† |
| Presence of metastatic LN on pathologic specimens**** (yes/no) | 18 / 19 | 5 / 16 | 0.0941 |
| Pathologic depth of invasion (T stage)*** | Basement membrane (Tis) | 0 | 3 |
| Mucosa (T1a) | 2 | 9 |
| Submucosa (T1b) | 11 | 11 |
| Muscularis propria (T2) | 9 | 0 |
| Adventitia (T3) | 15 | 0 |
| Invasion of adjacent structures (T4) | 0 | 0 |

*Pretreatment endoscopic evaluation was performed in 116 patients at our hospital
**Measurement of endoscopic length was impossible in 2 patients with total esophageal obstruction
***Measurement of pathologic length and depth of invasion was possible for 60 patients who were treated by surgery (n = 58) or ESD (n = 2). There was no T4 case in these patients
****Frequency test of pathologically confirmed metastatic LNs was performed for 58 operative patients
LN = lymph node; ESD = endoscopic submucosal dissection
†Statistically significant
there was only 1 case where the SUVmax of the ESCC was lower than 2.5 and the ML2.5 was zero.

ML_PHL, ML2.5, and ML40% were significantly correlated with EL (ML_PHL: \( p < 0.001 \), slope = 0.91, \( R^2 = 0.6464 \); ML2.5: \( p < 0.001 \), slope = 0.96, \( R^2 = 0.5789 \); ML40%: \( p < 0.001 \), slope = 0.49, \( R^2 = 0.3321 \)) (Figs. 4a-c). In Bland-Altman analyses (Fig. 4d-f), the biases between ML_PHL, ML2.5, and ML40% and EL were 0.1 cm (limits of agreement = −2.62 ~ 2.69 cm; SD = 1.3532), 0.7 cm (limits of agreement = −2.53 ~ 3.89 cm; SD = 1.6357), and 0.5 cm (limits of agreement = −2.87 ~ 3.83; SD = 1.7096), respectively. Bias and standard deviation were smallest for ML_PHL and EL. There was significant proportional error between ML2.5 and EL on the Bland-Altman plot (\( r = 0.3458, p = 0.0016 \)). No significant error was found between ML_PHL or ML40% and EL on the Bland-Altman plots (ML_PHL: \( r = 0.2102, p = 0.0597 \); ML40%: \( r = −0.2027, p = 0.0695 \)).

**Comparisons between MLs, EL, and PL**

Of the 121 study patients, PL measurements were performed in 60 (58 esophagectomy and 2 ESD patients) (Fig. 1). Among these 60 patients, 2 did not undergo EGD in our hospital. Correlation between EL and PL was assessed in 58 patients (56 esophagectomy and 2 ESD patients). EL was significantly correlated with PL (\( R^2 = 0.5482, \) slope = 0.77, \( p < 0.001 \)) (Fig. 5a). In Bland-Altman analysis (Fig. 5e) of the 58 patients, the bias between EL and PL was 0.3 cm (limits of agreement = −2.29 ~ 2.90 cm, SD = 1.3254 cm). There was no significant proportional error between EL and PL (\( r = 0.3458, p = 0.0016 \)). No significant error was found between ML_PHL or ML40% and PL on the Bland-Altman plots (ML_PHL: \( r = 0.2102, p = 0.0597 \); ML40%: \( r = −0.2027, p = 0.0695 \)).

**Effects of SUVmax on ML measurement**

We evaluated the differences between MLs (i.e., ML_PHL, ML2.5, and ML40%) and PL according to SUVmax of ESCC. The difference between ML_PHL and PL was only weakly correlated with SUVmax (Spearman correlation: \( \sigma = 0.372, p = 0.0254 \)). However, the difference between ML2.5 and PL showed a strong positive correlation with SUVmax (Spearman correlation: \( \sigma = 0.806, p < 0.0001 \)). In contrast to ML2.5, the difference between ML40% and PL was strongly negatively correlated with SUVmax (Spearman correlation: \( \sigma = −0.789, p < 0.0001 \)). These results suggested that ML_PHL was less affected by SUVmax of ESCC than were ML2.5 and ML40%.

**Table 3** Inter-observer agreement test for determination of PHL tumor threshold

| Observer A | 20% | 30% | 40% | 50% | 60% | 70% | 80% | 90% |
|------------|-----|-----|-----|-----|-----|-----|-----|-----|
| Observer B| 20% | 30% | 40% | 50% | 60% | 70% | 80% | 90% |
| 2%         |     |     |     |     |     |     |     |     |
| 1%         | 40% |     |     |     |     |     |     |     |
| 1%         | 13% |     |     |     |     |     |     |     |
| 2%         |     |     |     |     |     |     |     |     |
| 2%         |     |     |     |     |     |     |     |     |
| 1%         | 2%  |     |     |     |     |     |     |     |
| 5%         |     |     |     |     |     |     |     |     |
| 1%         |     |     |     |     |     |     |     |     |
| 2%         |     |     |     |     |     |     |     |     |

\( k = 0.936 \)

Jun et al. Cancer Imaging (2018) 18:35 Page 8 of 14
Changes in PHL tumor threshold according to SUVmax
We evaluated the relationship between PHL tumor threshold and SUVmax in 85 FDG avid ESCCs as described in a previous study [17]. PHL tumor threshold (i.e., % SUVmax determined by the PHL method) showed a strong inverse correlation with SUVmax ($r = -0.923$, $p < 0.0001$; Fig. 7a).

SUV at the PHL tumor threshold (i.e., SUVmax $\times$ PHL tumor threshold) showed a strong positive correlation with SUVmax ($r = 0.891$, $p < 0.0001$; Fig. 7b).

Discussion
The major finding of the current study is that SegPHL is more accurate and reliable for defining the tumor margin of ESCCs than are fixed threshold methods. In a previous study, Jun et al. [17] reported that SegPHL was more reliable than fixed threshold methods for delineation of the margins of thyroid cancers. However, the thyroid cancers examined in that study were very small and visually homogeneous. They reported that PHL abruptly increased in layer thickness and was located between the tumor and the background. In the present study, we demonstrated that SegPHL was also accurate in ESCCs, which can be large and/or visually heterogeneous. MLPHL was highly correlated with PL (Fig. 5), the bias and standard deviation of MLPHL were small on the Bland-Altman plot (Fig. 5), and there were no serious proportional errors visible on the plot. The absolute difference between MLPHL and PL was smaller than that of ML2.5 and ML40% (Fig. 6). MLPHL was less affected by SUVmax of the ESCC than were ML2.5 and ML40%. The PHL

Fig. 4 Regression analyses and Bland-Altman plots of MLPHL, ML2.5, and ML40% versus EL. MLPHL, ML2.5, and ML40% were significantly correlated with EL (a: $R^2 = 0.6464$, $p < 0.001$; b: $R^2 = 0.5789$, $p < 0.001$; c: $R^2 = 0.3321$, $p < 0.001$). Bias and standard deviation were smallest between MLPHL and EL (d-f).
tumor threshold (% of SUVmax) showed an inverse correlation with SUVmax (Fig. 7). The characteristics of the PHL were similar to those reported in a previous study [17]; PHL also showed an abrupt increase in layer thickness and was located between the tumor activity and the background. Furthermore, PHL tumor threshold changed according to SUVmax of the ESCC (Fig. 7), consistent with a previous PHL study [17].

The most widely used segmentation methods are SegSUV and Seg%. However, accurate tumor segmentation with a fixed threshold is impossible with these methods because the optimal tumor threshold changes according to SUVmax or signal-to-background ratio [13, 20, 21]. The volume of a tumor with faint FDG uptake is highly overestimated by Seg%. In addition, MTV using SegSUV underestimates the MTV of a tumor with low metabolic activity and overestimates that of a tumor with high metabolic activity [6]. These shortcomings of Seg% and SegSUV were also found in our present study. The difference between ML2.5 and PL was larger
when SUVmax was higher, and the difference between ML40% and PL was larger when SUVmax was lower. However, MLPHL was less affected by SUVmax. The results of our study suggest that the PHL method could accurately segment FDG avid tumor regardless of SUVmax.

SegVisual has been reported to be more accurate than the fixed threshold method in some cases [7]. Although accurate tumor segmentation may be possible with visual tumor delineation, the SegVisual has several limitations. First, the reproducibility of SegVisual is low [22]. Second, visual tumor perception can be altered by the PET window level setting and the color scale [23–25]. Third, the process is quite slow, because no auto-segmentation program is used.

The SegPHL could be considered as a SegVisual because it involves the visual location of the background and the PHL. However, there are several major differences between SegPHL and SegVisual. First, inter-observer agreement for the SegPHL is very good (Table 3), unlike with SegVisual. This good agreement may be due to the use of specific PHL image settings (i.e., PET window level: top = SUVmax, bottom = 0; color scale = 10-step color scale).

Among our study population of 121 cases, PHL tumor threshold was concordant in 111 (91.7%). The second difference between SegPHL and SegVisual is that SegPHL uses commercial auto-segmentation programs to measure MTVPHL with a known, accurate PHL tumor threshold (i.e., % of SUVmax). Use of an auto-segmentation program allows more rapid measurement of MTV than is possible with SegVisual.

SegPHL may also be similar to SegGradient. The unique characteristics of PHL are location between the tumor and the background and abrupt increase in layer thickness compared to the inner layer without significant distortion of tumor shape [17]. In the gradient method, the tumor margin is considered the point at which a large gradient change occurs in the PET/CT image [11]. A previous study suggested that PHL was very similar to the large gradient change of SegGradient [17]. We also hypothesized that the location of the PHL would likely be very similar to that of the large gradient change of SegGradient. Furthermore, like SegGradient [11], SegPHL was more accurate than fixed threshold methods. The main differences between SegPHL and SegGradient are as follows. First, PHL tumor threshold is determined by visual
inspection of the tumor using PHL image settings. In contrast, SegGradient is determined using a special workstation. Second, an accurate percentage threshold can be determined by SegPHL (i.e., % of SUVmax). However, there is no way to determine an accurate % threshold of SegGradient. Third, although SegPHL is similar to SegGradient, the exact point at which there is a large gradient change cannot be determined using SegPHL. In our study, we defined PHL tumor threshold as the starting point of the PHL (i.e., the innermost point of the PHL), as in Jun et al. [17]. However, the large gradient change of SegGradient could be located in the outermost point or in the middle of the PHL. Another consideration is that the large gradient change of SegGradient might not be represented by a single % of SUVmax (i.e., the SUV of the large gradient change may differ in different parts of the tumor).

SegAdaptive is based on calibrated curves, where accurate % threshold changes as signal-to-background ratio changes [6, 13]. In this method, as the signal-to-background ratio increases, the accurate % threshold decreases [13]. Clinicians can choose an optimal regression equation to determine the accurate % threshold. Based on a phantom study, SegAdaptive is superior to fixed threshold methods [13, 26]. In our present study,
PHL tumor threshold showed a strong inverse correlation with SUVmax of ESCC ($\sigma = -0.923$, $p < 0.0001$; Fig. 7a), as reported for SegAdaptive in the phantom study. Similarly, Jun et al. [17] reported that PHL tumor threshold was inversely correlated with SUVmax of thyroid cancer.

Several studies have compared ML, MTV, PL, and pathologic tumor volume [12, 21, 27, 28]. The results of these reports suggest that there is no single optimal SUV or % of SUVmax threshold that can be used to define an accurate tumor margin [6]. In our present study, PHL tumor threshold (%) showed a significant positive correlation with SUVmax of ESCC ($\sigma = 0.891$, $p < 0.0001$; Fig. 7b). Our results are consistent with previous studies that compared ML, MTV, PL, and pathologic tumor volume [12, 21, 27] and with a previous PHL study of thyroid cancer [17]. The number of cases where ML was compared with PL was similar between our present study and other previous studies (Zhong et al. [12]: $n = 37$ in esophageal cancer; Borakati et al. [28]: $n = 21$ in esophageal cancer).

An accurate tumor segmentation method should satisfy the following conditions. First, the segmented ML has to have a high degree of correlation with PL. Second, the bias and standard deviation should be small on Bland-Altman plots. Third, no serious proportional errors should be found in Bland-Altman analysis. Fourth, the segmented ML should not be highly affected by SUVmax of ESCC. Fifth, the segmented ML should correlate strongly with EL. Among MLPHL, ML2.5, and ML40%, only MLPHL satisfied these conditions. Although ESCCs in our present study were definitely larger and more visually heterogeneous than the thyroid cancers examined in a previous PHL study [17], SegPHL was the most accurate segmentation method among SegPHL, SegSUV, and Seg%. Therefore, we conclude that SegPHL is far more accurate than fixed threshold methods.

Our study had several limitations. First, the study design was a retrospective analysis. Thus, there might have been operator-dependent bias in the measurement of EL and PL. Second, comparison of MTV and pathologic tumor volume was impossible because a vertical incision along the esophagectomy specimen had to be performed to evaluate pathologic depth of invasion. The vertical incision process changed the ellipsoid tumor shape of the ESCC into a planar shape. Because a change in tumor shape could introduce serious bias, we only assessed the correlation between ML and PL. Third, PL was measured after formalin fixation, which could shrink the esophagectomy specimen.

Conclusion
In conclusion, SegPHL was more accurate than fixed threshold methods compared with PL. PHL tumor threshold was adjusted according to SUVmax of ESCC. We conclude that SegPHL might be used to accurately define the tumor margins of ESCCs.

Abbreviations
CCRT: concurrent chemoradiation therapy; EGD: esophagogastroduodenoscopy; EL: endoscopic tumor length; ESCC: esophageal squamous cell carcinoma; ESD: endoscopic submucosal dissection; FDG: F-18 fluorodeoxyglucose; ML: metabolic tumor length; ML2.5: metabolic tumor length using SUV 2.5 threshold; ML40%: metabolic tumor length using fixed 40% of SUVmax threshold; MLPHL: metabolic tumor length using the peritumoral halo layer method; MTV: metabolic tumor volume; PHL: peritumoral halo layer; PL: pathologic tumor length; SegAdaptive: segmentation using the adaptive threshold method; SegGradient: segmentation using the gradient method; SegPHL: segmentation using the PHL method; SegSUV: segmentation using fixed SUV threshold; SegVisual: segmentation using visual delineation; SUV: standardized uptake value; SUVmax: maximum standardized uptake value; TLG: total lesion glycolysis

Acknowledgements
We would like to thank Dr. Hyo Sang Lee for statistical consultation and Dr. Bum Soo Kim for assisting with the review of FDG PET/CT images.

Ethical approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The present study was retrospective; for this type of study, the local ethics committee waived formal consent.

Contents for publication
Not applicable.

Funding
No funding was received.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
SJ and YS wrote the manuscript and contributed to study conception. JP contributed to data collection and helped with image analyses. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Nuclear Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan 49297, South Korea. 2Department of Radiology, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan 49297, South Korea. 3Department of Nuclear Medicine, Busan Seongsan Hospital, Suyeong-ro, Nam-gu, Busan 48453, Republic of Korea.
References

1. Lematignier C, Di Fiore F, Mane C, Hapdey S, Modzelewski R, Gouel P, et al. Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:2008–16. https://doi.org/10.1007/s00259-014-2899-y.

2. Surucu E, Demir Y, Sengoz T. The correlation between the metabolic tumor volume and hematological parameters in patients with esophageal cancer. Ann Nucl Med. 2015;29:906–10. https://doi.org/10.1007/s12149-015-1020-4.

3. Van de Weele C, Kruse V, Sneets P, Sathkege M, Maes A. Predictive and prognostic value of metabolic tumor volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging. 2013;40:290–301. https://doi.org/10.1007/s00259-012-1990-z.

4. Hollis AC, Quinn LM, Hodson J, Evans E, Flownight J, Begum R, et al. Prognostic significance of tumor length in patients receiving esophagectomy for esophageal cancer. J Surg Oncol. 2017;116:1114–22. https://doi.org/10.1002/jso.24789.

5. Roedl JB, Sahani DV, Colen RR, Fischman AJ, Mueller PR, Blake MA. Tumour length measurement on PET-CT predicts the most appropriate stage-dependent therapeutic approach in oesophageal cancer. Eur Radiol. 2008;18:2833–40. https://doi.org/10.1007/s00330-008-0789-1.

6. Im HJ, Bradhaw T, Solayapam M, Cho SY. Current methods to define metabolic tumor volume in positron emission tomography: which one is better? Nucl Med Mol Imaging. 2018;5:25–15. https://doi.org/10.1007/s13139-017-0493-6.

7. Jeganathan R, McGuigan J, Campbell F, Lynch T. Does pre-operative estimation of oesophageal tumour metabolic length using 18F-fluorodeoxyglucose PET/CT images compare with surgical pathology length? Eur J Nucl Med Mol Imaging. 2011;38:656–62. https://doi.org/10.1007/s00259-010-1670-3.

8. Heron DE, Andrade RS, Flickinger CJ, Johnson J, Agarwala SS, Wu A, et al. Hybrid PET-CT simulation for radiation treatment planning in head-and-neck cancers: a brief technical report. Int J Radiat Oncol Biol Phys. 2004;60:1419–24. https://doi.org/10.1016/j.ijrobp.2004.05.037.

9. Doyeux K, Vachon S, Hapdey S, Daoqu J, Eden-Sanson A, Vera P, et al. Reproducibility of the adaptive thresholding calibration procedure for the delineation of 18F-FDG-PET-positive lesions. Nucl Med Commun. 2013;34:432–8. https://doi.org/10.1097/MNM.0b013e3283f8e5e7.

10. Hatt M, Cheze-Le Rest C, van Baardwijk A, Lambin P, Pradier O, Visvikis D. Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation. J Nucl Med. 2011;52:1690–7. https://doi.org/10.2967/jnumed.110.078501.

11. Schingoli DA, Span PN, Oyen WJ, Kaanders JH. Can FDG PET prediction radiation treatment outcome in head and neck cancer? Results of a prospective study. Eur J Nucl Med Mol Imaging. 2011;38:1449–58. https://doi.org/10.1007/s00259-011-1789-x.

12. Lee JA. Segmentation of positron emission tomography images: some recommendations for target delineation in radiation oncology. Radiother Oncol. 2010;96:302–7. https://doi.org/10.1016/j.radonc.2010.07.003.

13. Njeh CF. Tumor delineation: the weakest link in the search for accuracy in radiotherapy. J Med Phys. 2008;33:136–40. https://doi.org/10.1007/s00259-007-1401-x.

14. Bielhl KJ, Cossio F, Dahm DL, Jiang YW, Miller SA, Cooper JS, et al. Comparison of tumor volumes as determined by pathologic examination and FDG-PET/CT images of non-small-cell lung cancer: a pilot study. Int J Radiat Oncol Biol Phys. 2009;74:1468–74. https://doi.org/10.1016/j.ijrobp.2009.01.019.

15. Brakataki A, Razack A, Cawthorne C, Roy R, Usmani S, Ahmed N. A comparative study of quantitative assessment with fluorine-18-fluorodeoxyglucose positron-emission tomography and endoscopic ultrasound in oesophageal cancer. Nucl Med Commun. 2018;39:628–35. https://doi.org/10.1097/MMN.0000000000001844.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions